Navigation Links
Generex Subsidiary Antigen Express Announces Press Conference at American Association for Cancer Research Related to the Immunological Response of its AE37 Vaccine to Prevent Recurrence of Breast Cancer
Date:4/3/2012

WORCESTER, Mass. and TORONTO, April 3, 2012 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB: GNBT.OB) announced today that the American Association for Cancer Research (AACR) chose to spotlight a presentation on data from the ongoing clinical trial of AE37, an immunotherapeutic vaccine to prevent relapse in patients who have had breast cancer being developed by Antigen Express, in a press conference.  The annual AACR meeting is one of the largest national cancer conferences in the US, highlighting the most significant advances in all areas of cancer research.  It is being held this year from March 31 to April 4 at McCormick Place in Chicago, Il.

The specific presentation highlighted by the AACR is entitled: "Immune response assessment in a phase II trial of AE37 HER2 peptide vaccine" by Dr. Diane Hale et al.  The abstract will be available for viewing Tuesday April 3rd from 8 AM to 12 PM.  The study examined patients from the controlled, randomized trial of AE37 for immunological response to the vaccine.  AE37 consists of a fragment of the HER2 protein modified by proprietary means to increase potency in generating a specific immune response to HER2 expressing cancer cells.  The key findings from the study are that patients receiving AE37 indeed developed a specific immune response as indicated by an increase in circulating T cells in their blood specific for the HER2 fragment as well as a positive skin test (delayed type hypersensitivity).  In addition, patients receiving AE37 demonstrated a reduction in T regulatory cells, which are know to be able to hamper an immune response.

The AACR press conference was held Monday April 2nd.  Dr. Hale gave a brief oral presentation of the study followed by a question and answer period.

"The finding that AE37 generates a specific immune response is consistent with the activity we've observed to date, suggesting that patients receivi
'/>"/>

SOURCE Generex Biotechnology Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Generex Announces Patent Award for its Core Vaccine Technologies in Japan
2. Generex Secures Commitments for $3.6M Capital Raise
3. Generex Subsidiary Antigen Express Provides Update on AE37 Cancer Vaccines Clinical & Regulatory Strategy
4. Breast Cancer Vaccine Being Developed by Generex Subsidiary Antigen Express to be Featured on Bloomberg Television Today
5. Leading Investigator to Present Clinical Data on Generex Oral-lyn™ at International Diabetes Federation Meetings in Dubai
6. Generex Provides Update on Generex Oral-lyn™ Clinical & Regulatory Program
7. Generex Makes Podium Presentation of Clinical Data on Generex Oral-lyn™ at European Association for the Study of Diabetes Annual Meeting
8. Generex Provides Update on Spinout of Antigen Express
9. Generex Augments Cash Position With Sales of Non-Essential Assets
10. Amarantus BioSciences and Generex Biotechnology Collaborate on Cell Therapy for Late Stage Diabetes
11. Generex Announces Publication of Studies with the Mayo Clinic Confirming and Extending the Antigen Express Ii-Key Platform Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... July 24, 2014   Cypher Genomics, Inc., ... appointment of Adam Simpson as president ... rapid and comprehensive annotation and interpretation of individual ... "Cypher,s technology has the potential to ... enhancing diagnostic accuracy, optimizing therapeutic approaches and reducing ...
(Date:7/23/2014)... NEW YORK , July 24, 2014 /PRNewswire/ ... and Immune Pharmaceuticals Inc. (OTCQX and NASDAQ OMX ... "IMNP."; "Immune" or "the Company"), announced a collaboration ... bullous pemphigoid last night at an event attended ... other interested parties. Lyfebulb is a health and ...
(Date:7/23/2014)... efforts have made great strides in saving China,s endangered ... are over 65 giant panda reserves that have been ... efforts, just 1596 pandas remain in the wild. ... to save the panda by improving genetic diversity, avoid ... Just how are these high-profile programs doing so far? ...
(Date:7/23/2014)... , July 23, 2014 /PRNewswire-iReach/ -- Think Drinks ... performance for the long term. They are the first ... of sustained energy as an alternative to the temporary ... Drinks on Indiegogo on July 29, 2014, with hopes ... campaign. Photo - http://photos.prnewswire.com/prnh/20140723/129697 ...
Breaking Biology Technology:Cypher Genomics Announces the Appointment of Adam Simpson as President and COO to Advance Transformative Genome Interpretation Technology 2Cypher Genomics Announces the Appointment of Adam Simpson as President and COO to Advance Transformative Genome Interpretation Technology 3Innovative Collaboration To Increase Awareness Of Bullous Pemphigoid, A Rare Autoimmune Disease Of The Skin 2Innovative Collaboration To Increase Awareness Of Bullous Pemphigoid, A Rare Autoimmune Disease Of The Skin 3Innovative Collaboration To Increase Awareness Of Bullous Pemphigoid, A Rare Autoimmune Disease Of The Skin 4Innovative Collaboration To Increase Awareness Of Bullous Pemphigoid, A Rare Autoimmune Disease Of The Skin 5truBrain Neuroscientists To Launch More Effective, Healthier Alternative To Energy Drinks On Indiegogo 2
... 11 /Xinhua-PRNewswire-FirstCall/ -- BMP,Sunstone Corporation (Nasdaq: BJGP ... due to the technical difficulties encountered on,today,s conference ... tomorrow,Wednesday, November 12, 2008. On this call, BMP ... since technical difficulties prevented the,Company from addressing all ...
... Rapid Detection Flu A+B Test Differentiates Flu Strains A ... 20 percent of the U.S. population becomes ill with ... bacterial infections,present similarly to influenza. Because of this, overuse ... to the growing problem of,antibiotic resistance., This flu ...
... Contamination by an unknown,organism often calls for ... organism can be identified and eliminated. Such ... and productivity of medical device,and pharmaceutical manufacturers ... Microbial ID Breakthrough: How DNA Sequencing,Services Help ...
Cached Biology Technology:BMP Sunstone to Host Follow-Up 3Q08 Conference Call Due to Technical Difficulties Encountered on Tuesday's Call 2BMP Sunstone to Host Follow-Up 3Q08 Conference Call Due to Technical Difficulties Encountered on Tuesday's Call 3MultiVu Video Feed: New Rapid Test to Diagnose Flu May Help With Upcoming Flu Season 2White Paper Details How DNA Sequencing Services Can Prevent Cleanroom Shutdowns at Medical Device and Pharmaceutical Manufacturers 2White Paper Details How DNA Sequencing Services Can Prevent Cleanroom Shutdowns at Medical Device and Pharmaceutical Manufacturers 3
(Date:7/24/2014)... N.J. A yearlong study funded by the New ... Edward J. Bloustein School of Planning and Public Policy ... in Sandy-affected towns are skeptical about the likelihood of ... survey respondents, 45 percent indicated they were "pessimistic" or ... by Superstorm Sandy would be rebuilt better than they ...
(Date:7/24/2014)... This news release is available in German . ... that there are 300 million asthma sufferers worldwide, a ... up to 30% of the global population contending with ... inflammatory diseases can also affect other organs and parts ... occur in the intestine (in the form of inflammatory ...
(Date:7/24/2014)... 2014 NXT-ID, Inc., (NXTD: OTCQB) a biometric authentication company ... smart wallet, Wocket™, was recently the topic of  an interview ... Gino Pereira , CEO of NXT-ID, on July ... Mr. Gino Pereira explains how the ... cards and walks host Anita Finley through ...
Breaking Biology News(10 mins):Rutgers study explores attitudes, preferences toward post-Sandy rebuilding 2New drugs to combat asthma and the like 2New drugs to combat asthma and the like 3Boomer Times Gets to Know NXT-ID's Next Generation Wocket Smart Wallet; Practical, Secure and Easy to Use 2Boomer Times Gets to Know NXT-ID's Next Generation Wocket Smart Wallet; Practical, Secure and Easy to Use 3Boomer Times Gets to Know NXT-ID's Next Generation Wocket Smart Wallet; Practical, Secure and Easy to Use 4
... , Coordinated by Innsbruck University Botanic Garden, with ... INQUIRE is a practical, one-year, continual professional development ... eleven European countries. Its focus on inquiry-based science ... education community that IBSE methods are more effective ...
... Manipulation of cells by a new microfluidic device may ... the body,s own immune cells to fight such diseases ... neuroblastoma. The therapy, known as adoptive T cell ... treatment involves removing disease-fighting immune cells called T cells ...
... mutation responsible for type 2 diabetes in nearly 10 percent ... originated in Italy and was validated at UCSF, found that ... in the body,s ability to make insulin receptors the ... sugar. This drop in insulin receptors leads to insulin resistance ...
Cached Biology News:Hands-on learning turns children's minds on to science 2Researchers predict age of T cells to improve cancer treatment 2Researchers predict age of T cells to improve cancer treatment 3Type 2 diabetes linked to single gene mutation in 1 in 10 patients 2
Goat polyclonal to CHMP5 ( Abpromise for all tested applications). Antigen: Synthetic peptide: C-NKDGVLVDEFGLPQ, corresponding to C terminal amino acids 202-215 of Human CHMP5 Entrez GeneID: ...
Rabbit polyclonal to Reptin/TIP49B/RUVB2 ( Abpromise for all tested applications). Antigen: Synthetic peptide (Human) Entrez Gene ID: 10856 Swiss Protein ID: Q6FIB9...
Goat polyclonal to ORC2L ( Abpromise for all tested applications). entrezGeneID: 4999 SwissProtID: Q13416...
14-3-3 tau Antibody Shipping Temperature: HOT Storage Temperature: -20C...
Biology Products: